Cytek Biosciences CEO Wenbin Jiang says advances in flow cytometry are improving healthcare decision-making by delivering more precise, actionable data. The com

Cytek Biosciences CEO Wenbin Jiang says advances in flow cytometry are improving healthcare decision-making by delivering more precise, actionable data. The company is also backing spectral flow cytometry research and running a summer reagent incentive program.